-
公开(公告)号：EP2344648B1
公开(公告)日：2018-11-14
申请号：EP09816967.5
申请日：2009-09-26
申请人： Tocagen Inc.
IPC分类号： C12N15/52 , C12N5/10 , C12N15/867 , C07K14/39 , C12N9/10 , C07K14/55 , C07K14/57 , C12N9/78 , C07K16/28 , C12N15/113
CPC分类号： C12N7/00 , A61K2039/505 , C07K14/55 , C07K14/57 , C07K16/2818 , C07K2317/622 , C07K2319/00 , C12N9/1077 , C12N9/78 , C12N15/113 , C12N15/86 , C12N2310/141 , C12N2740/13043 , C12N2840/102 , C12N2840/203 , C12Y305/04001
摘要： This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
-
公开(公告)号：EP2346995B1
公开(公告)日：2018-11-07
申请号：EP09820986.9
申请日：2009-09-26
申请人： Tocagen Inc.
CPC分类号： C12N7/00 , A61K2039/505 , C07K14/55 , C07K14/57 , C07K16/2818 , C07K2317/622 , C07K2319/00 , C12N9/1077 , C12N9/78 , C12N15/113 , C12N15/86 , C12N2310/141 , C12N2740/13043 , C12N2840/102 , C12N2840/203 , C12Y305/04001
摘要： This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
-
公开(公告)号：EP2605783B1
公开(公告)日：2015-03-25
申请号：EP11748282.8
申请日：2011-08-19
申请人： Lauer, Ulrich M. , Bitzer, Michael , Lampe, Johanna , Zimmermann, Martina , Berchtold, Susanne , Lange, Sebastian , Neubert, Wolfgang J. , Bossow, Sascha
发明人： Lauer, Ulrich M. , Bitzer, Michael , Lampe, Johanna , Zimmermann, Martina , Berchtold, Susanne , Lange, Sebastian , Neubert, Wolfgang J. , Bossow, Sascha
CPC分类号： A61K35/768 , A61K31/7088 , C07K2319/00 , C12N7/00 , C12N9/1077 , C12N9/78 , C12N2760/18421 , C12N2760/18432 , C12N2760/18443 , C12N2760/18471 , C12N2830/60 , C12Y305/04001
摘要： The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.
-
公开(公告)号：EP4426821A1
公开(公告)日：2024-09-11
申请号：EP22814570.2
申请日：2022-10-28
发明人： SONTHEIMER, Erik , XUE, Wen , ZHANG, Han , BAMIDELE, Nathan , DONG, Xiaolong
CPC分类号： C12N9/22 , C12N9/78 , C12N15/62 , C12Y305/04004 , C12Y305/04001 , C07K2319/0920130101 , C12N9/2497 , C12Y302/02027
-
公开(公告)号：EP2582726B1
公开(公告)日：2018-10-31
申请号：EP11738959.3
申请日：2011-06-21
发明人： CIANFRIGLIA, Maurizio , FLEGO, Michela , ASCIONE, Alessandro , FIORI, Valentina , DOMINICI, Sabrina , MALLANO, Alessandra , MORICOLI, Diego , ZAMBONI, Silvia
IPC分类号： C07K16/30 , C12N9/88 , A61K39/395
CPC分类号： C07K19/00 , A61K2039/505 , C07K14/55 , C07K14/70503 , C07K16/3007 , C07K2317/40 , C07K2317/622 , C07K2317/94 , C07K2319/00 , C07K2319/02 , C07K2319/33 , C07K2319/40 , C07K2319/50 , C07K2319/55 , C07K2319/95 , C12N9/80 , C12Y305/04001
摘要： An anti-CEA scFv having an uncleaved Pel B leader sequence is surprisingly stable and is highly specific for CEA and CEACAM1.
-
公开(公告)号：EP2420242A1
公开(公告)日：2012-02-22
申请号：EP10008726.1
申请日：2010-08-20
申请人： Lauer, Ulrich M. , Bitzer, Michael , Lampe, Johanna , Zimmermann, Martina , Berchtold, Susanne , Lange, Sebastian , Neubert, Wolfgang , Bossow, Sascha
发明人： Bitzer, Michael , Lampe, Johanna , Zimmermann, Martina , Berchtold, Susanne , Lange, Sebastian , Neubert, Wolfgang , Bossow, Sascha
CPC分类号： A61K35/768 , A61K31/7088 , C07K2319/00 , C12N7/00 , C12N9/1077 , C12N9/78 , C12N2760/18421 , C12N2760/18432 , C12N2760/18443 , C12N2760/18471 , C12N2830/60 , C12Y305/04001
摘要： The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.
摘要翻译： 本发明涉及一种药物组合物，其包含编码自杀基因的重组麻疹病毒，所述重组麻疹病毒用于治疗对具有无自杀基因活性的溶瘤麻疹病毒的一级或二级抗性的恶性细胞。 此外，本发明涉及一种基于编码自杀基因的麻疹疫苗株Schwarz的重组麻疹病毒，其包含胞嘧啶脱氨酶，特别是酵母胞嘧啶脱氨酶和尿嘧啶磷酸核糖转移酶，特别是酵母尿嘧啶磷酸核糖转移酶的融合， 用于制备本文所要求的重组麻疹病毒的试剂盒。
-
公开(公告)号：EP2344648A2
公开(公告)日：2011-07-20
申请号：EP09816967.5
申请日：2009-09-26
申请人： Tocagen Inc.
IPC分类号： C12N15/867 , C12N15/52
CPC分类号： C12N7/00 , A61K2039/505 , C07K14/55 , C07K14/57 , C07K16/2818 , C07K2317/622 , C07K2319/00 , C12N9/1077 , C12N9/78 , C12N15/113 , C12N15/86 , C12N2310/141 , C12N2740/13043 , C12N2840/102 , C12N2840/203 , C12Y305/04001
摘要： This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
摘要翻译： 本公开提供了修饰的胞嘧啶脱氨酶（CDs）。 本公开还涉及表达或包含这种修饰的CD的细胞和载体以及在治疗疾病和病症中使用这些修饰的CD的方法。
-
公开(公告)号：EP4375373A3
公开(公告)日：2024-08-21
申请号：EP24155880.8
申请日：2014-12-12
CPC分类号： C12N15/102 , C12Y304/22062 , C12Y305/04001 , C12N9/6472 , C07K2319/8020130101 , A61K38/465 , A61K38/50 , C12Y305/04004 , C12Y305/04005 , C12N9/78 , C12N15/01 , C12Y305/04 , C12Y301/00 , C12N9/22 , C12Y301/22 , A61P11/00 , A61P13/02 , A61P13/12 , A61P17/00 , A61P19/00 , A61P21/00 , A61P25/00 , A61P25/28 , A61P3/00 , A61P35/00 , Y02A50/30
摘要： Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing enzymes or domains, are provided.
-
公开(公告)号：EP3402496A1
公开(公告)日：2018-11-21
申请号：EP17738957.4
申请日：2017-01-12
IPC分类号： A61K35/545 , C12N5/00 , C12N5/04 , C12N15/63
CPC分类号： C12N5/0696 , A61K35/545 , C07K14/005 , C07K14/4702 , C12N9/1211 , C12N9/78 , C12N15/85 , C12N2501/60 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/605 , C12N2501/606 , C12N2501/608 , C12N2506/11 , C12N2510/00 , C12N2710/16231 , C12N2800/108 , C12N2820/60 , C12N2830/003 , C12N2830/006 , C12Y207/01021 , C12Y305/04001
摘要： The invention relates generally to methods of generating induced pluripotent stem cells (iPSCs) that do not contain the reprogramming vector. In some embodiments, the invention relates to inducing pluripotency in somatic cells by introducing an episomal vector(s) comprising at least one expression cassette containing reprogramming factors and/or synthetic transcription factors and a suicide gene. In some embodiments, the invention relates to inducing pluripotency in somatic cells by introducing episomal vector(s) comprising expression cassettes containing reprogramming factors and/or synthetic transcription factors and a transcriptionally regulated EBNA-1 gene. In some embodiments, the invention relates to inducing pluripotency in somatic cells by introducing episomal vector(s) comprising expression cassettes containing reprogramming factors and/or synthetic transcription factors and both a suicide gene and a transcriptionally regulated EBNA-1 gene.
-
公开(公告)号：EP3080265A1
公开(公告)日：2016-10-19
申请号：EP14825518.5
申请日：2014-12-12
IPC分类号： C12N9/78
CPC分类号： C12N9/22 , A61K38/465 , A61K38/50 , A61K47/61 , C07K2319/00 , C07K2319/80 , C12N9/6472 , C12N9/78 , C12N15/01 , C12N15/102 , C12P19/34 , C12Q1/6883 , C12Q2600/156 , C12Y301/00 , C12Y301/22 , C12Y304/22062 , C12Y305/04 , C12Y305/04001 , C12Y305/04004 , C12Y305/04005
摘要： Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant von Willebrand Factor protein to correct a point mutation associated with a disease or disorder, e.g., with von Willebrand disease. The methods provided are useful for correcting a vWF point mutation within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing enzymes or domains, are provided.
摘要翻译： 本公开的一些方面提供可用于核酸的定向编辑的策略，系统，试剂，方法和试剂盒，包括编辑例如人基因组内的细胞或受试者基因组内的单个位点。 在一些实施方案中，Cas9的融合蛋白与核酸编辑酶或酶结构域例如 ，脱氨酶域，提供。 在一些实施方案中，提供了用于靶向核酸编辑的方法。 在一些实施方案中，提供用于产生靶向核酸编辑蛋白质的试剂和试剂盒，例如Cas9的融合蛋白和核酸编辑酶或结构域。
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.032 秒)
